How to Get Leqvio (Inclisiran) in New Hampshire

What Is Leqvio and Why Does It Matter for New Hampshire Patients?

Leqvio is the brand name for inclisiran, a small interfering RNA (siRNA) therapy that silences hepatic PCSK9 production, which lets LDL receptors recycle more efficiently and remove LDL-C from the bloodstream. The FDA approved inclisiran in December 2021 for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering beyond maximally tolerated statin therapy. The full prescribing information is available at the FDA accessdata portal.

New Hampshire has roughly 1.37 million residents. Cardiovascular disease remains the leading cause of death nationally, accounting for approximately 1 in 5 deaths according to CDC vital statistics data. Familial hypercholesterolemia affects about 1 in 250 people in the general population, meaning roughly 5,400 New Hampshire residents may carry the condition, the majority undiagnosed or undertreated.

Inclisiran's twice-yearly dosing schedule after the initial loading phase separates it from daily oral medications and even from the monthly or bimonthly PCSK9 monoclonal antibodies (evolocumab, alirocumab). That reduced injection frequency can improve adherence meaningfully for patients who struggle with daily pill burdens or monthly injection schedules.

The Clinical Evidence Behind Leqvio

The phase 3 ORION-10 and ORION-11 trials, published in the New England Journal of Medicine in March 2020, provide the primary efficacy basis for inclisiran's approval. ORION-10 and ORION-11 (N=3,457 combined) demonstrated that inclisiran 284 mg reduced LDL-C by 50% (ORION-10) and 49.9% (ORION-11) versus placebo at day 510, both P<0.001. Rates of discontinuation due to adverse events were comparable to placebo in both trials.

The ORION-4 cardiovascular outcomes trial, enrolling more than 15,000 patients with pre-existing ASCVD, is ongoing and will report major adverse cardiac event (MACE) data. Interim mechanistic data already confirm that sustained PCSK9 suppression persists between doses, which is the pharmacological rationale for the six-month interval.

The American College of Cardiology / American Heart Association 2022 cholesterol guidelines state: "For patients with ASCVD at very high risk, if LDL-C remains ≥70 mg/dL on maximally tolerated statin plus ezetimibe, it is reasonable to add a PCSK9 inhibitor." Inclisiran, as a PCSK9 synthesis inhibitor rather than a binding antibody, falls within the spirit of this recommendation, and many cardiologists now include it in that tier. The AHA clinical guidance page provides the full 2022 document.

A 2023 pooled analysis from the ORION program covering 3,660 patient-years of exposure found no new hepatotoxicity signals and no meaningful increase in myopathy risk, addressing a common question from patients already managing statin side effects. That safety analysis appeared in JAMA Cardiology.

Who Qualifies for Leqvio in New Hampshire?

FDA-approved indications are specific. Inclisiran is indicated for adults who have:

1. HeFH with LDL-C that remains elevated despite maximally tolerated statin therapy (with or without ezetimibe), or
2. Clinical ASCVD (prior MI, stroke, or peripheral arterial disease) with LDL-C persistently above goal on maximally tolerated statin therapy.

Homozygous familial hypercholesterolemia (HoFH) is not an approved indication for inclisiran, distinguishing it from evolocumab, which does carry an HoFH label.

A practical qualification checklist for New Hampshire clinicians reviewing a patient chart for inclisiran candidacy:

• Confirmed HeFH by Dutch Lipid Clinic Network score ≥6, genetic panel positive for pathogenic LDL-receptor variant, or clinical diagnosis documented by a board-certified lipidologist, OR documented clinical ASCVD event.
• LDL-C at or above 70 mg/dL (for ASCVD patients) or 100 mg/dL (for HeFH without ASCVD) despite at least 4-6 weeks on the highest tolerated statin dose.
• Ezetimibe trial documented or contraindication noted. Most commercial payers and NH Medicaid programs require documented ezetimibe use (or intolerance) before approving a PCSK9-targeting agent.
• Baseline labs completed within 90 days: fasting lipid panel, ALT/AST, creatinine, eGFR, TSH.
• No active liver disease (Child-Pugh B/C excluded in the ORION trials).
• Pregnancy status documented; inclisiran is not recommended during pregnancy due to absence of human safety data per the prescribing label.

How to Get a Leqvio Prescription in New Hampshire: Step by Step

Getting inclisiran in New Hampshire follows a predictable sequence. The steps below apply whether you use a local cardiologist, a primary care clinician, or a telehealth provider.

Step 1: Initial consultation and labs. Book an appointment with a prescriber holding an active New Hampshire license. Telehealth is fully permitted under New Hampshire's telehealth statute (RSA 329:1-d), which allows clinicians licensed in NH to prescribe controlled and non-controlled medications via synchronous audio-video visits. Inclisiran is not a controlled substance, so it faces no additional telehealth prescribing barriers. The prescriber will review your cardiac history, current medications, and order a fasting lipid panel if one is not on file from the past 90 days.

Step 2: Prescriber submits prior authorization. Nearly every commercial insurer operating in New Hampshire, including Anthem BCBS NH, Harvard Pilgrim Health Care, and Tufts Health Plan, requires prior authorization (PA) for inclisiran. The PA packet typically needs: current LDL-C result, documentation of statin therapy (dose and duration), ezetimibe trial or intolerance documentation, and the confirmed HeFH or ASCVD diagnosis code. Processing takes 3-10 business days for standard review; expedited review for clinically urgent cases runs 24-72 hours under NH insurance regulations.

Step 3: Specialty pharmacy fulfillment. Leqvio is distributed exclusively through a specialty pharmacy network. Novartis works with Accredo Health Group and CVS Specialty as primary dispensing pharmacies. The specialty pharmacy ships the pre-filled syringe directly to the prescriber's office, a home-health agency, or an infusion center depending on the administration plan.

Step 4: Clinician-administered injection. Inclisiran must be given by a licensed healthcare professional; it is not a patient self-inject medication. In New Hampshire, this means you will receive the injection at a clinician's office, a cardiology practice, a home-health nurse visit, or a licensed infusion center. The injection itself takes under five minutes subcutaneously in the abdomen, upper arm, or thigh.

Step 5: Monitoring and repeat dosing. The second dose is given at day 90 (three months after the first). After that, dosing is every six months. A repeat fasting lipid panel at 90 days and again at the six-month mark allows the prescriber to document response. Most patients see maximum LDL-C reduction by day 150-180.

Telehealth Providers in New Hampshire Prescribing Leqvio

New Hampshire's telehealth statute covers clinician-patient relationships formed via audio-video platforms, and no separate registration is required beyond holding an active NH license. HealthRX providers licensed in New Hampshire can initiate inclisiran management remotely for patients who meet criteria. This matters most for residents of rural NH counties (Coös, Grafton, Carroll) where cardiologist access may require 60-120 minute drives to Concord, Manchester, or Dartmouth Hitchcock in Lebanon.

Telehealth visits for inclisiran management typically include: chart review, lab interpretation, PA submission support, coordination with the specialty pharmacy, and standing orders for the administering nurse. The injection itself still requires an in-person encounter with a licensed professional, but that step can be handled by a local primary care office acting under the telehealth prescriber's orders in a collaborative care model.

The Ryan Haight Online Pharmacy Consumer Protection Act does not restrict inclisiran prescribing via telehealth because inclisiran is not a scheduled substance under the Controlled Substances Act.

Prior Authorization Requirements for New Hampshire Insurers

Prior authorization is the single most common reason for delays in starting inclisiran. The documentation that NH commercial payers most frequently require includes:

• Most recent LDL-C value (dated within 90 days, from a lab-processed fasting sample, not a point-of-care finger-stick).
• Statin therapy documentation: name of statin, dose, duration. Payers typically require at least 3 months on maximum tolerated dose. Anthem BCBS NH has required documentation of two different statins tried if the patient is labeled "statin intolerant."
• Ezetimibe trial: most plans require 3 months on ezetimibe 10 mg or documented intolerance before approving any PCSK9-targeting therapy.
• Diagnosis confirmation: ICD-10 code E78.01 (familial hypercholesterolemia, heterozygous) or I25.10 / I25.110 for ASCVD. Genetic test results or a lipidologist's letter strengthens the file considerably.
• Prescriber attestation that lifestyle modification has been addressed.

If the initial PA is denied, New Hampshire law requires insurers to provide a written denial reason and instructions for appeal within 60 days. The external appeal process under RSA 420-J:5 allows an independent review organization to overturn medically inappropriate denials. Success rates for inclisiran PA appeals improve substantially when the appeal includes a published guideline statement (such as the 2022 AHA/ACC cholesterol guideline) and the treating cardiologist's clinical letter.

Cost and Coverage in New Hampshire

New Hampshire Medicaid (NH DHHS, administered through managed care organizations) does not currently cover inclisiran. Patients on Medicaid in NH should discuss evolocumab (Repatha) or alirocumab (Praluent), both of which have broader Medicaid formulary access in New Hampshire.

For commercially insured patients, Novartis offers the Leqvio Connect patient support program, which can reduce out-of-pocket costs to $0 for eligible patients. Income limits and insurance status requirements apply; patients can enroll via the Novartis support line or through the prescribing pharmacy.

Without insurance, the average wholesale price (AWP) for inclisiran runs approximately $3,400-$3,600 per dose as of mid-2025. Given twice-yearly maintenance dosing, annual drug costs before negotiated discounts approach $7,000. The Novartis patient assistance program (Leqvio 360 Support) covers uninsured patients meeting income criteria at or below 600% of the federal poverty level.

Medicare Part B coverage applies when inclisiran is administered in a physician's office (it is billed as a Part B drug under the incident-to billing model), which differs from self-inject PCSK9 antibodies that fall under Part D. This distinction makes inclisiran particularly attractive for Medicare patients with high Part D cost-sharing, since Part B cost-sharing is generally lower for administered drugs when the 20% coinsurance cap is met through a Medigap plan.

503A Compounding of Inclisiran in New Hampshire

503A pharmacies in New Hampshire are state-licensed compounding pharmacies operating under USP Chapter 797 sterile compounding standards and New Hampshire Board of Pharmacy regulations. They may prepare patient-specific preparations when a valid practitioner-patient relationship exists and a commercially available product is not suitable for a specific patient's clinical need.

Inclisiran 284 mg as Leqvio is a commercially approved product. Compounding an essentially identical copy of an FDA-approved drug without a documented clinical difference is generally prohibited under the FD&C Act Section 503A. A 503A NH pharmacy could theoretically prepare an inclisiran formulation only if the patient had a documented allergy to an excipient in the commercial product or if the commercial product was on FDA's drug shortage list. As of mid-2025, inclisiran is not on FDA's shortage list. Patients should be cautious of any pharmacy offering compounded inclisiran outside these narrow conditions, as the regulatory basis would be questionable and clinical safety data for the compounded product would be absent.

Labs Needed Before Starting Leqvio in New Hampshire

Lab requirements serve two purposes: confirming candidacy and establishing a baseline for monitoring. The minimum pre-treatment panel recommended by the ORION trial protocols and consistent with standard lipidology practice includes:

• Fasting lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides, non-HDL-C). Must be fasting for at least 9-12 hours. LDL-C calculated by Friedewald equation is acceptable unless triglycerides exceed 400 mg/dL, in which case a direct LDL-C measurement is preferred.
• Comprehensive metabolic panel (CMP): ALT, AST, alkaline phosphatase, bilirubin, creatinine, eGFR, electrolytes. Active hepatic disease excludes patients per the prescribing label.
• TSH: Hypothyroidism can raise LDL-C independently and should be optimally treated before attributing residual LDL-C elevation solely to FH or ASCVD.
• HbA1c or fasting glucose (recommended, not strictly required): Documents baseline glycemic status since cardiovascular risk management often runs in parallel with diabetes management.
• Urine albumin-to-creatinine ratio (UACR): Relevant in patients with CKD co-managing cardiovascular risk.

Results from a laboratory operating under CLIA certification are required for PA submissions. Point-of-care finger-stick lipid panels from a health fair or pharmacy kiosk are not accepted by most NH insurers for prior authorization purposes.

Who Can Prescribe Leqvio in New Hampshire?

New Hampshire authorizes the following clinician types to prescribe non-controlled medications:

• MD or DO with an active NH medical license and DEA registration (DEA not required for inclisiran specifically, but typically held).
• Nurse Practitioner (APRN-NP) with a New Hampshire prescriptive authority license. New Hampshire APRNs practice without mandatory physician oversight (RSA 326-B), so an NP may independently prescribe inclisiran.
• Physician Assistant (PA) with a New Hampshire PA license. PAs in NH practice with a supervising physician agreement but may prescribe independently for non-controlled substances within their scope when the supervising agreement permits.

Cardiologists, lipidologists, endocrinologists, and internal medicine physicians are the most common prescribers. Primary care NPs and PAs with cardiovascular risk management experience also prescribe inclisiran in NH, particularly in community health centers and rural settings.

Transferring an Existing Leqvio Prescription to New Hampshire

If you are moving to New Hampshire from another state and have an established inclisiran prescription, the transfer process requires a prescriber holding an active NH license. Inclisiran is not a refillable medication in the traditional sense; it is a scheduled injection administered and billed by a clinician. The practical steps are:

1. Obtain records from your previous cardiologist or prescriber: the original PA approval letter, most recent lipid panel, and current medication list.
2. Establish care with an NH-licensed prescriber (in-person or telehealth).
3. The new NH prescriber submits a new PA to your NH insurer using the transferred records as supporting documentation. Most NH payers will honor a recently approved out-of-state PA if it is still within the approval window (typically 12 months), though they may require a new NH-specific review.
4. The specialty pharmacy updates your shipping address and administering site to an NH-based location.

A gap in dosing of 4-6 weeks beyond the scheduled injection date does not appear to cause rebound LDL-C overshoot based on ORION pharmacokinetic modeling, though prompt resumption is preferable. The ORION-10 NEJM publication provides the pharmacokinetic durability data supporting this.

Monitoring After Starting Leqvio in New Hampshire

After the first injection, clinical monitoring follows a structured timeline. A fasting lipid panel at day 90 (before the second injection) documents initial LDL-C response. A second panel at day 150-180 captures the trough-to-steady-state LDL-C, which is the number most relevant to long-term cardiovascular risk. Liver function tests are not mandated at every visit by the label, but most NH lipidologists repeat them at 6 months given that hepatic PCSK9 expression is the drug's target tissue.

Per the ACC/AHA 2022 guidelines, an LDL-C reduction of 50% or a resultant LDL-C below 70 mg/dL (very high risk) or below 55 mg/dL (extreme risk) constitutes an adequate treatment response. Patients not achieving this threshold despite confirmed injections should prompt a medication adherence check, reassessment of underlying thyroid or renal disease, and consideration of combination PCSK9 antibody plus inclisiran therapy under specialist guidance (off-label, supported by mechanistic rationale given differing mechanisms of action).